News and Announcements
Lighthouse Digital Approved to List On Unlisted Securities Exchange (“USX”)
- Published September 17, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Lighthouse Digital Limited is pleased to advise that it has been approved by the board of Unlisted Securities Exchange (“USX”) to list the shares in LHD Group Limited on the USX under the ticker “LHD”, with trading approved to start on the 12th October 2020.
Says Lighthouse Digital CEO Ian Bailey, says, “This is a major step forward for the LHD group as it gives us the opportunity to further develop and grow the business, bring in additional capital and add shareholder value.”
The Unlisted Securities Exchange (USX) is a cost-efficient and simple share trading platform for small to medium-sized companies to provide liquidity and keep their shareholders informed and operates in several distinct markets for equity and debt securities.
Trading in securities quoted on USX is undertaken via approved Brokers. Current Issuers include Bluesky Meats, Rangatira, SilverFern Farms, Skyline Enterprises, Syft Technologies, Zespri and the total market capitalisation of its Issuers is approximately $2.9b.
About Lighthouse Digital Limited
Lighthouse Digital is an end-to-end provider in the rapidly growing Digital Marketing, Digital Signage and Digital Advertising segment. We offer a full range of products and services, including large outdoor and indoor billboards. Our software is also used as a self-managed digital signage for the international markets on a SaaS model.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
